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TREATMENT OF CHRONIC HEART FAILURE 
(CHF): IMPROVING SURVIVAL BUT NOT 
HEALTH-RELATED QUALITY OF LIFE (HRQL)
Chassany O, Mahe I, Duracinsky M
Therapeutic Research Unit, Lariboisiere Hospital, Paris, France
OBJECTIVE: Treatments such as ACE inhibitors and
beta-blockers reduce mortality in CHF. Demonstration
of a parallel improvement of HRQL would appear of
good added value. METHOD: A critical appraisal of
published controlled trials used the guidance document
and the checklist developed by ERIQA. RESULTS: Al-
though a reduction of mortality and NYHA score was
demonstrated in a few large studies, none was able to
show a clear and unbiased HRQL improvement vs. pla-
cebo. Several major issues that would increase the confi-
dence in the results are not presented or missing: hypoth-
eses of changes in HRQL scores and power estimation;
justification of the choice of questionnaires (e.g. 6 ques-
tionnaires were used in a trial and presented as HRQL,
some of them being a dyspnoea score or a global evalua-
tion of change, with no explanation whether they were
covering different concepts, and without selecting the
most important questionnaire for the primary statistical
analysis); validation data (e.g. a trial used 14 subscales
taken from 3 different validated questionnaires. Is the re-
sultant questionnaire still valid?); statistical analysis plan;
description and imputation of missing data; statement
that the analysis is in intent to treat. In the majority of
trials, small differences were observed for a few subscales
among many, or only at some assessments over time.
When the difference reaches statistical significance, it is
only because of the large sample, but it has no clinical
signification. Even for the physical subscale which may
be of importance in CHF, small non significant effect
sizes are observed. Some explanations have been proposed
for these results: non severe patients included, questionnaire
not reliable or responsive. CONCLUSION: There is con-
cern to conclude that despite attempts of publications
and general reviews to enhance the modest results, there
is no definite demonstration that HRQL is improved by
treatment which reduces mortality in CHF.
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SAVINGS ACHIEVED IN AN HMO SPONSORED 
PRIMARY CARE BASED DISEASE MANAGEMENT 
AND CASE MANAGEMENT INITIATIVE
Fisher FJ1, Sidorov J2, Fox G2, Girolami S2, Dobeck L2, 
Donmoyer C2, Riehl P2, Shull R2, Wolke O3
1Schellen & Partners, Düsseldorf, Germany; 2Care Coordination 
Department, Geisinger Health Plan, Danville PA, USA; 
3Schellen and Partners, Danville, PA, USA
OBJECTIVE: To describe the cost savings achieved in
HMO sponsored primary care-based case management
and disease management programs in asthma, diabetes
mellitus and congestive heart failure (CHF). METHODS:
Continuously enrolled participants’ total per member per
month (PMPM) charges for medical services one year
prior and one year after entry into HMO sponsored case
management and disease management programs were
compared during fiscal year January 1, 1998 to March
31, 2000. The HMO sponsored programs recruited pa-
tients in the primary care setting and relied on clinical
guidelines and HMO employed patient education nurses
and case management nurses. This initiative is based in
55 primary care sites serving 295,000 insureds across
northeastern and central Pennsylvania in the United States.
RESULTS: 327 patients with asthma had baseline PMPM
of $311, which dropped to $274 PMPM after entry. In
diabetes, 3,953 patients had a baseline PMPM of $468
that dropped to $434. The baseline PMPM dropped from
$1,748 to $1,402 for 870 patients with CHF. For 965
patients receiving case management, the baseline PMPM
was $1,074 and it dropped to $887. Total reductions in
claims over one year for each program was $112,524,
$1,264,052, $2,587,068 and $1,516,784, respectively
with a total reduction in health care claims of $5,480,428.
CONCLUSION: While these claims data may be limited
by a lack of statistical significance and by regression to
the mean, they suggest that case management and disease
management programs in asthma, diabetes and conges-
tive heart failure may be able to achieve significant finan-
cial savings compared to baseline levels of utilization.
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SUPPORTING IMPLEMENTATION OF 
PRESCRIPTION GUIDELINES IN MEDICAL 
WARDS: A RANDOMIZED TRIAL
Fontaine A, Vinceneux P, Fiessinger JN, Bergmann JF, Dhote 
R, Cohen P
Collégiale de Médecine Interne, Assistance Publique-Hôpitaux 
de Paris, Paris, France
OBJECTIVE: To evaluate the acceptability and effective-
ness of a “guided prescription” form implementing lo-
cally developed guidelines for preventive anticoagulation.
METHODS: Thirty internal medicine wards were ran-
domly assigned to either intervention (I) or control (C)
group. I-group physicians were asked to use the guided
prescription form whenever they considered prescribing
preventive anticoagulation over a 2-month period. One-
day surveys of all patients hospitalized in I and C wards
were conducted before and after this intervention period.
Physicians were also asked to rate independently whether
preventive anticoagulation was required for a series of
isolated or combined risk factors (1–9 scale), and to as-
sess several attributes of the form (4-degree Likert scale).
RESULTS: Of 313 completed prescription forms col-
lected from I wards during the intervention period, 262
(84%) followed recommendations; an explicit “other”
option was used for 36 additional patients (12%). Before
and after surveys showed an overall decrease from 41%
(146/358) to 33% (121/365) (95% CI: 11% to 4%)
in the prevalence of preventive anticoagulation in I
wards, while prescriptions remained stationary at 38%
(154/402 and 134/352) in C wards. While scores as-
